The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Roche's Tecentriq in combination with Avastin and chemotherapy as an initial treatment for lung cancer.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.